Astera Labs (ALAB) had a rough Monday. The stock dropped about 13% as a mix of profit-taking, insider stock sales, and index rebalancing weighed on shares. But zoom out a bit, and the picture is still pretty rosy: the stock is up more than 113% year-to-date.
The broader market wasn't helping either. The Nasdaq fell 1.74% and the S&P 500 slipped 0.68%, as a global risk-off mood took hold. Semiconductor stocks were particularly hit after weakness in South Korea, where Samsung Electronics and SK Hynix dragged down the KOSPI index, and that weakness spilled over into U.S. chip names.
Investors also got cautious after the U.S. launched another round of strikes against Iran late Sunday. That pushed crude oil prices higher and weighed on equity futures. The U.S. Central Command said the Iranian government no longer controlled the Strait of Hormuz, raising concerns about potential disruptions to global energy supplies and higher costs for the semiconductor industry.
On top of all that, SEC filings revealed that Astera Labs' board chairman, Manuel Alba, and director Stefan Dyckerhoff executed multi-million dollar stock liquidations. These were automated sales under Rule 10b5-1 trading plans, so they were pre-planned and not a reaction to current events. Alba sold 173,366 shares across several tranches at prices ranging from $442.01 to $458.38, while Dyckerhoff sold 12,500 shares at $450.
The stock also saw some volatility from the Nasdaq-100 index reconstitution, which added Astera Labs to the index effective June 22. While that created buying pressure from passive funds ahead of the inclusion, the recent trading sessions reflect broader index rebalancing adjustments. Meanwhile, market participants are rotating capital out of high-momentum growth names and into defensive sectors like Health Care and Utilities.
Technically, the stock has pulled back 12.8% below its 20-day simple moving average of $405.34, signaling that short-term momentum has shifted to sellers. But the longer-term trend remains intact. Astera Labs still trades 7.7% above its 50-day moving average of $328.34 and well above its 200-day moving average of $200.39. The golden cross formed in May is still in place. The relative strength index (RSI) is at 46.04, indicating neutral momentum—cooled from June's overbought levels but not yet oversold.
Immediate resistance sits near $372.50, while key support is around $303.00 if selling pressure continues. At the time of publication Monday, Astera Labs shares were down 13.45% at $399.00.
